BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 2205352)

  • 1. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia.
    Woods WG; Ruymann FB; Lampkin BC; Buckley JD; Bernstein ID; Srivastava AK; Smithson WA; Benjamin DR; Feig SA; Kim TH
    Cancer; 1990 Sep; 66(6):1106-13. PubMed ID: 2205352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group.
    Woods WG; Kobrinsky N; Buckley JD; Lee JW; Sanders J; Neudorf S; Gold S; Barnard DR; DeSwarte J; Dusenbery K; Kalousek D; Arthur DC; Lange BJ
    Blood; 1996 Jun; 87(12):4979-89. PubMed ID: 8652810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
    Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
    J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of childhood acute nonlymphocytic leukemia with high-dose cytosine arabinoside, 6-thioguanine, and doxorubicin without maintenance therapy: pilot study ANLL-80 of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; Hhlen K; Colly LP; Vossen JM
    Pediatr Hematol Oncol; 1988; 5(2):93-102. PubMed ID: 3152962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
    Stein RS; Vogler WR; Winton EF; Cohen HJ; Raney MR; Bartolucci A
    Leuk Res; 1990; 14(10):895-903. PubMed ID: 2259226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
    Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
    Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study.
    Steuber CP; Civin C; Krischer J; Culbert S; Ragab A; Ruymann FB; Ravindranath Y; Leventhal B; Wilkinson R; Vietti TJ
    J Clin Oncol; 1991 Feb; 9(2):247-58. PubMed ID: 1988573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission maintenance for acute nonlymphocytic leukemia: cytosine arabinoside plus 6-thioguanine versus a sequence of drug regimens.
    Presant CA; Berger NA; Klahr C; Phillips GL
    Cancer; 1980 Jul; 46(1):22-8. PubMed ID: 6930320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly.
    Kahn SB; Begg CB; Mazza JJ; Bennett JM; Bonner H; Glick JH
    J Clin Oncol; 1984 Aug; 2(8):865-70. PubMed ID: 6379120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA.
    Mandelli F; Vegna ML; Avvisati G; Amadori S; Spadea A; Cacciola E; Cantore N; De Laurenzi A; De Rosa C; Fioritoni G
    Ann Hematol; 1992 Apr; 64(4):166-72. PubMed ID: 1581404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
    Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia.
    Loeb DM; Bowers DC; Civin CI; Friedman AD
    Med Pediatr Oncol; 2001 Oct; 37(4):365-71. PubMed ID: 11568900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary results of intensive therapy of children and adolescents with acute nonlymphocytic leukemia--a Childrens Cancer Study Group report.
    Lampkin BC; Woods WG; Buckley JD; Hammond GD
    Haematol Blood Transfus; 1990; 33():210-4. PubMed ID: 1691130
    [No Abstract]   [Full Text] [Related]  

  • 15. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study.
    Ravindranath Y; Steuber CP; Krischer J; Civin CI; Ducore J; Vega R; Pitel P; Inoue S; Bleher E; Sexauer C
    J Clin Oncol; 1991 Apr; 9(4):572-80. PubMed ID: 2066754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission induction therapy: the more intensive the better?
    Büchner T; Hiddemann W; Berdel W; Wörmann B; Löffler H; Schoch C; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Andreesen R; Balleisen L; Haase D; Eimermacher H; Aul C; Rasche H; Uhlig J; Grüneisen A; Reis HE; Hartlapp J; Hirschmann WD; Weh HJ; Pielken HJ; Gassmann W; Sauerland MC; Heinecke A
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S41-4. PubMed ID: 11587366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
    Vogler WR; Winton EF; Gordon DS; Raney MR; Go B; Meyer L
    Blood; 1984 May; 63(5):1039-45. PubMed ID: 6201211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial.
    Rees JK; Gray RG; Swirsky D; Hayhoe FG
    Lancet; 1986 Nov; 2(8518):1236-41. PubMed ID: 2878130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
    Sorrell AD; Alonzo TA; Hilden JM; Gerbing RB; Loew TW; Hathaway L; Barnard D; Taub JW; Ravindranath Y; Smith FO; Arceci RJ; Woods WG; Gamis AS
    Cancer; 2012 Oct; 118(19):4806-14. PubMed ID: 22392565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study.
    Rytting M; Ravandi F; Estey E; Cortes J; Faderl S; Garcia-Manero G; Jeha S; Ouzounian S; Pierce S; Kantarjian H
    Cancer; 2010 Nov; 116(22):5272-8. PubMed ID: 20665501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.